NIH R01 · 2025
PROJECT SUMMARY The use of anti-obesity medications (AOMs) is rapidly increasing, driven by the approval of newer incretin- based treatments, including both GLP-1 receptor agonists and combination GLP-1/GIP receptor agonists. Despite their efficacy, discontinuation rates for these medications are high, and stopping treatment often leads to rapid and significant weight regain. Intervening with behavioral intervention after AOM discontinuation may reduce the steep regain curve. However, it is currently unclear how to engage with these patients quickly to improve long-term weight management and health benefits. Primary care clinics are essential settings for intervention after AOM…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.